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Targeting the affective brain—a randomized controlled trial of
real-time fMRI neurofeedback in patients with depression
David M. A. Mehler1,2, Moses O. Sokunbi3, Isabelle Habes2, Kali Barawi1,2, Leena Subramanian1,2, Maxence Range4, John Evans2,
Kerenza Hood5, Michael Lührs6,7, Paul Keedwell1,8, Rainer Goebel6,7 and David E. J. Linden1,2,9
Functional magnetic resonance imaging neurofeedback (fMRI-NF) training of areas involved in emotion processing can reduce
depressive symptoms by over 40% on the Hamilton Depression Rating Scale (HDRS). However, it remains unclear if this efficacy is
specific to feedback from emotion-regulating regions. We tested in a single-blind, randomized, controlled trial if upregulation of
emotion areas (NFE) yields superior efficacy compared to upregulation of a control region activated by visual scenes (NFS). Forty-
three moderately to severely depressed medicated patients were randomly assigned to five sessions augmentation treatment of
either NFE or NFS training. At primary outcome (week 12) no significant group mean HDRS difference was found (B=−0.415 [95%
CI −4.847 to 4.016], p= 0.848) for the 32 completers (16 per group). However, across groups depressive symptoms decreased by
43%, and 38% of patients remitted. These improvements lasted until follow-up (week 18). Both groups upregulated target regions
to a similar extent. Further, clinical improvement was correlated with an increase in self-efficacy scores. However, the interpretation
of clinical improvements remains limited due to lack of a sham-control group. We thus surveyed effects reported for accepted
augmentation therapies in depression. Data indicated that our findings exceed expected regression to the mean and placebo
effects that have been reported for drug trials and other sham-controlled high-technology interventions. Taken together, we
suggest that the experience of successful self-regulation during fMRI-NF training may be therapeutic. We conclude that if fMRI-NF is
effective for depression, self-regulation training of higher visual areas may provide an effective alternative.
Neuropsychopharmacology (2018) 0:1–8; https://doi.org/10.1038/s41386-018-0126-5
INTRODUCTION
Depression has been recognized as the largest contributor to
disability globally, and around one third of patients are thought
not to respond to available treatments [1]. New efforts in the
development of both pharmacological and non-pharmacological
therapies are therefore needed. The last decade has seen
considerable investment in the evaluation of innovative neuro-
modulatory therapies, particularly deep brain stimulation, but thus
far this technique has not been superior to sham interventions [2].
Another way of targeting the brain directly is through
neurofeedback training, a technique that has been increasingly
explored to treat psychiatric conditions including depression [3, 4].
Neurofeedback can enable patients to develop personal strategies
that are effective in self-regulating brain areas and networks
associated with mental imagery through the feedback of signals
that reflect their own neural activation patterns. Hence, the
underlying principle of most neurofeedback protocols is super-
vised mental imagery training [5]. Mental imagery can be
therapeutic for depression by increasing cognitive flexibility and
capacity for positive mental simulation [6]. With neurofeedback
patients’ engagement in mental imagery can be enhanced by
monitoring and feeding back the associated brain activation.
In one pilot study, we demonstrated that patients suffering
from mild to moderate depression learnt to upregulate brain areas
using real-time fMRI neurofeedback (fMRI-NF). Target areas
included the insula and lateral prefrontal areas, which were
localized with positive affective visual stimulation. Moreover, only
the group that had completed fMRI-NF training, but not a mental
imagery only control group, experienced significant improvement
in mood within four training sessions [7]. These findings have
recently been corroborated in a double-blind, placebo-controlled
randomized clinical fMRI-NF trial that used affective mental
imagery training in unmedicated depressed patients. This trial
found over 40% reduction in depressive symptoms in the
intervention, but not in the placebo neurofeedback group [8].
However, the participants in the placebo group of that trial could
not self-regulate their control target regions as well as the
experimental group, suggesting that groups were not matched for
the reward experience. Hence, it remains unclear whether the
clinical efficacy of fMRI-NF in depression is specific to feedback
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from brain regions involved in affective processing, or whether the
general experience of self-regulation may be in itself therapeutic.
We report the results from a randomized controlled trial (RCT) of
fMRI-NF training in medicated patients with moderate to severe
depression. The current trial compared upregulation of brain areas
involved in emotion processing (NFE) with an active control
procedure that involved upregulation of brain areas involved in
higher visual processes (NFS). Specifically, both groups were
provided with information that enabled patients to upregulate
selected target areas. Whereas the NFE group was guided to
imagine positive images similar to those seen in the respective
blocks of the localizer run [7], the NFS group was guided to
imagine relaxing scenes [9]. This design gave patients of the
control group also the opportunity for self-regulation success and
reward experience. We hypothesized that neurofeedback of
emotion areas would produce clinical improvements exceeding
those seen in the active control group.
METHOD
Patient recruitment
The study was approved in January 2012 by the South East Wales
Research Ethics Committee and registered in February 2012
(NCT01544205). The first patient started the study in March 2012.
All patients provided written informed consent. They were
compensated for their time and travel costs in cash. Patients were
recruited via general practitioner (GP) surgeries and Community
Mental Health Teams (CMHTs) in South Wales and the National
Centre for Mental Health (NCMH). To be included patients had to
meet the following criteria: a diagnosis of unipolar depression,
currently moderate or severe, confirmed with the Mini Interna-
tional Neuropsychiatric Interview (MINI), and current antidepres-
sant treatment (with no change of dose in the preceding three
months). We excluded psychotic symptoms, current substance
dependence, eating disorders, claustrophobia and other MRI
contraindications, and ongoing non-pharmacological treatment.
Randomization and masking
Patients were randomly assigned to one of two groups using an
adaptive randomization protocol developed by the South East
Wales Trials Unit (SEWTU). The randomization protocol allocated
patients to two groups, minimizing for differences in age, gender,
duration of illness, medication type (with three categories: SSRI
only; non-SSRI antidepressant; combination treatment) and base-
line depression severity as measured with the Hamilton Depres-
sion Rating Scale (HDRS-17). After the patient had consented and
completed all baseline measures, these were entered in a
computer program (scripted in Microsoft Excel) and an allocation
provided to the investigators conducting the study. Investigators
running the MRI sessions needed to know group allocation in
order to run the appropriate imaging protocols, but those
conducting the assessments were blind to group allocation.
Trial design
The intervention in both groups consisted of five training sessions,
starting with four weekly sessions followed by a consolidation
session after a break of 1 month to test if patients retained the
ability to self-regulate target (regions of interest) ROIs. The third
session served as transfer session during which no neurofeedback
was provided to test if patients can upregulate target ROIs based
on successful strategies learned during the previous two
neurofeedback sessions. The last neurofeedback session occurred
approximately 4 weeks after the 4th session to test if patients
retained similar upregulation success. The actual duration of the
intervention period was on average 12 weeks because of the need
to schedule sessions around patients’ availability. Before the
randomization, baseline measures of all clinical outcomes were
recorded. Clinical measures were recorded again after the fifth
neurofeedback session (week 12), and at follow up (FU; on average
week 18 after start of the intervention). All patients who
completed the trial received verbal debriefing at FU.
Clinical and psychometric measures
The primary outcome measure was group mean difference in the
Hamilton Depression Rating Scale (HDRS-17) [10] at the end of the
intervention (session 5), which was administered by a clinician
who was blinded to treatment group. Secondary clinical outcome
measures were the group difference in the HDRS at follow-up and
the group differences at both time points in the Hospital Anxiety
and Depression Scale (HADS) [11] anxiety and depression
subscales, the Quality Of Life scale (QOLS) [12] and EuroQol
research foundation questionnaire (EQ-5D-5L), which assessed the
subject’s health utility. The following self-rated psychometric
measures were also acquired before and after the intervention
and at follow-up: thought Control Ability Questionnaire (TCAQ)
[13] to measure the perceived ability to control unwanted,
intrusive thoughts, Thought Control Questionnaire (TCQ) [14] to
measure the effectiveness of strategies used for the control of
unpleasant and unwanted thoughts, the Self-Efficacy Scale (SES)
to measure optimistic self-beliefs to cope with difficult life
demands, with subscales for General Self-Efficacy (GSE) and Social
Self-Efficacy (SSE) [15], the Behavioral Inhibition System and
Behavioral Activation System (BIS/BAS) [16] to assess approach
and avoidance motivation.
Power calculation
The data from our pilot study [7] yielded an effect size (Cohen’s d) of
1.5 for the group difference in HDRS-17 improvement between
active neurofeedback and a control intervention. Expecting a slightly
more conservative effect size of 1.2, we estimated that a sample size
of 15 patients in each group would achieve > 80% power for post-
hoc t-tests (Bonferroni corrected, alpha-level 0.025, two-sided) and
set a recruitment target of 40 patients to allow for 25% attrition.
Although this effect size is unusual for add-on medication
treatments, similar effect sizes have been reported for some non-
pharmacological interventions [17], as well as for fMRI-NF compared
to sham [8]. Furthermore, because fMRI-NF is still in the early phases
of clinical evaluation and there is no agreement on the most suitable
comparators for clinical trials it seemed prudent to take logistic and
economic factors into consideration when setting up the trial.
MR image acquisition and neurofeedback training
A 3 Tesla whole-body MRI system (General Electric, Milwaukee,
USA) with an 8-channel head coil was used at the Cardiff
University Brain Research Imaging Centre (CUBRIC). To identify
target ROIs for neurofeedback training, each session began with a
functional localizer (325 volumes, first 6 volumes discarded to
ensure T1 equilibrium magnetization). An echo planar imaging
(EPI) sequence (TR= 2 s, TE= 45ms, flip angle= 80°, 30 slices,
field of view= 192mm, image matrix 64×64, in plane voxel size=
3×3mm, slice thickness= 4mm, gap of 1 mm) was used for fMRI,
and a high-resolution 3D T1-weighted image (TR 7.9 s, TE 3.0 ms, TI
450ms, flip angle 20°, matrix size 256×256, 1 mm isotropic voxel
resolution) was acquired for anatomical co-registration. To control
for physiological confounding factors of the BOLD signal [18],
heart rate (HR) and respiration volume per time (RVT) were
measured using pulse oximetry and a respiratory belt, respec-
tively, and recorded with Spike2 (version 5.21, Cambridge
Electronics Design Limited, Cambridge, UK).
fMRI-NF setup
Acquired EPI data was submitted to real-time motion correction
and spatial smoothing (FWHM 4mm). For the localizer scan, real-
time statistical analyses were carried out via an incremental
general linear model (GLM) using Turbo-BrainVoyager (TBV)
(Version 3.0, Brain Innovation, Maastricht, The Netherlands). Target
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ROIs in the respective groups were identified during a localizer
scan based on the t-statistic of the contrasts of interest, which
were defined as positive vs. neutral pictures in the NFE group and
scene vs. face pictures in the NFS group. Target ROIs in the NFE
group were limited to limbic and frontal portions of the anterior
cerebrum based on models of emotion processing in the human
brain [19]. This focus also helped to exclude areas involved in early
visual processing. For the localizer scans of the NFE group, we
used a previously described procedure [7] using pictures rated as
positive, negative and neutral from the International Affective
Pictures System (IAPS) [20]. We aimed for a control condition that
would entail similar upregulation success and thus reward
experience in both groups. Thus, the NFS group was presented
with visual stimuli showing faces, scenes, and animals to localize
higher visual brain areas. Patients in both groups were presented
with four series of four pictures (1.5 s each) per category in
pseudorandom order with alternating presentation and fixation
baseline blocks. The parahippocampal place area (PPA) was
chosen as the main target region in the NFS group. The PPA
has been identified with the presentation of neutral scene stimuli
[21, 22], but it is also activated during mental imagery of scenes
[23], and can be upregulated with fMRI-NF [9].
The localizer scan was followed by six neurofeedback runs (100
volumes, first 6 volumes discarded to ensure T1 equilibrium
magnetization), each containing four 20 s upregulation blocks
alternating with 20 s rest blocks (the first rest block was 40 s long).
Neurofeedback was provided with a visual thermometer display
projected onto the screen in the scanner and provided
continuously (i.e., updated with each volume) as described
previously [7]. Real-time statistical analyses were carried using
Turbo-BrainVoyager (TBV) (Version 3.0, Brain innovation, Maas-
tricht, The Netherlands). The signal intensity of target areas was
measured as the percent signal change (PSC) relative to baseline
(see Suppl. Methods). Both groups were instructed to increase
activation in their target areas during the upregulation periods
and were informed that using imagery of positive stimuli (NFE) or
imagery of scenes (NFS) might be a potential starting strategy.
However, patients were not restricted in their mental strategies
and could use any strategy that would enable them to achieve
this. Moreover, patients were asked to practice successful mental
imagery strategies at home between training sessions. For offline
fMRI analyses, motion parameters and physiological measures (HR
and RVT) were included as nuisance regressors in the General
Linear Model (see Suppl. Methods).
Statistical tools and analysis
The primary and secondary outcome measures for patients with
complete data were analyzed using Statistical Package for Social
Science (SPSS, version 23). To test for any significant differences
between groups, linear regression analyses were performed on the
outcome measures post-intervention (separately for the primary
endpoint after session 5 and for the follow-up session) with pre-
intervention scores as regressors of no interest. Further, the
following regressors of no interest were entered to reflect the
minimization procedure applied during randomization: gender, age,
duration of illness, medication type, the score for the respective
outcome variable at baseline, and HDRS-17 score at baseline. We
deemed a Bonferroni-corrected p < 0.002 (p= 0.05/21 tests) to be
appropriate for the secondary outcome measures. We also analyzed
pre-post differences within group means. For all pre-post compar-
isons, % change and 95% confidence intervals of the changes in
scores were calculated separately for both groups. Remission was
defined by an HDRS-17 score ≤ 7, and remission rates were
calculated based on all patients for whom we had complete data
up to the relevant time point. Effect sizes (ES) of clinical outcome on
the HDRS-17 were quantified using Hedges g based on difference
scores with respect to baseline for both session 5 (post-intervention)
and FU. Confidence intervals were bootstrapped based on 10,000
iterations using the R package bootES (version 1.3–20) [24]. Given
the absence of group effects for HDRS (Results section), we also
conducted post-hoc tests for evidence for a null effect (see Suppl.
Methods and Suppl. Results). Obtained t-test values of ROI analyses
were submitted to two-sided t-tests for each session to test for
activation at group level. p-values were adjusted based on the false
discovery rate (FDR) to corrected for multiple testing [25]. Given the
absence of a group effect in upregulation and the similar clinical
effects observed in both groups we also conducted equivalence
tests based on participants’ median ROI t values across the four
neurofeedback training sessions [26]. The test was conducted with a
Welch t-test (corrected for unequal variances) and with a SESOI=
−0.7 to 0.7 [with raw score lower limit 90% CI=−1.799 and upper
limit 90% CI= 1.799].
Clinical effects and self-efficacy
Self-efficacy describes an individual’s self-reported capacity to
cope with challenges [27]. To test whether pre-post changes in
self-efficacy (combined scores general and social self-efficacy
score) predicted changes in depression scores, we carried out a
regression analysis on residualized HDRS-17 scores of the primary
endpoint (session 5). Specifically, to minimize potential confound-
ing by baseline HDRS-17 and baseline self-efficacy scores, we
regressed these in a first step from HDRS-17 scores at the primary
endpoint. Obtained residuals were submitted to a robust
(iteratively weighted least squares) regression analysis [28].
RESULTS
Clinical outcomes
The patient flow is summarized in the CONSORT diagram (Fig. 1).
Recruitment ended in June 2014 when the target was achieved,
Fig. 1 CONSORT diagram of clinical trial
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and the last follow-up assessment was completed in September
2014. A total of 32 patients (16 in each group) completed the
intervention. All 32 patients were included in the analysis of
clinical, psychometric, and neuroimaging data at the primary
endpoint. Further, 28 of 32 patients (88%) also attended follow-up
and were included in the analysis of clinical and psychometric
data at follow up. Randomization was successful such that
there were no group differences at baseline in gender, age,
handedness, HDRS-17, duration of depressive disorder or medica-
tion (Table 1). Second-rater scores for the HDRS-17 were available
for 12 sessions, with high interrater correlation (Pearson’s
correlation: r= 0.95, p < 0.001).
There was no significant difference between groups on HDRS-
17 (B=−0.415, [95% CI −4.847 to 4.016], p= 0.848) or any of the
secondary outcome measures at the primary endpoint (see
Table S1 and Suppl. Results section 2.3, including Bayesian
analysis of covariance (ANCOVA) and equivalence tests). All pre-
post comparisons of clinical and psychometric outcomes across
the three sessions (baseline, end of intervention, and follow up)
are documented in Table S2. Depressive symptoms in both groups
improved similarly on the HDRS-17 (NFE: −8.34 [95% CI −4.92 to
−11.77]; NFS:−8.34 [95% CI −5.81 to −10.87]; Fig. 2a) and
secondary outcome measures. The NFE group improved by 42%
on the HDRS-17, the NFS improved by 44%. Overall, the effect
size for HDRS-17 was g= 1.46 [95% CI 0.97 to 1.95] at session 5
(NFE g= 1.23; [95% CI 0.63 to 1.92] vs. NFS g= 1.67 [95% CI 0.94 to
2.48]) and depression scores decreased by about 43% [95% CI 24
to 64%] across groups.T
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Fig. 2 Main clinical outcome measure HDRS-17 for NFE and NFS
groups at baseline, post-intervention, and follow up. a Mean and
standard error of the mean (SEM) HDRS scores, b remission rate in %
age based on HDRS, c Robust regression analysis between change in
total self-efficacy scores, and residualized HDRS-17 scores at primary
endpoint. *p < 0.05
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Figure 2b shows the remission rates, which was overall 37.5%
[95% CI 22.9 to 54.8%; 12/32 patients] with 25% for NFE (4/16
patients) and 50% for NFS (8/16 patients). There was no significant
difference between groups on the HDRS-17 (B=−1.121 [95% CI
−4.948 to 2.706], p= 0.548) or any of the secondary clinical
outcome measures at follow-up (Table S1). Both groups improved
compared to baseline on the HDRS-17 (NFE: −9.65 [95% CI −6.25
to −13.06]; NFS: −11.53 [95% CI −8.61 to −14.45]) and the
secondary outcome measures. At FU, the NFE group had improved
by 48% on the HDRS-17 compared to baseline, and the NFS group
had improved by 59%. The overall effect size for HDRS-17
improvement at FU was g= 1.88 [95% CI 1.24 to 2.54]; (NFE: g=
1.57 [95% CI 1.04 to 2.14] vs. NFS: g= 2.05 [95% CI 0.96 to 3.72]).
Figure 2b shows the overall remission rate remained at 37.5%
(NFE= 31%; NFS= 44%). Group differences of outcomes of other
psychological measures were largely not significant and those that
were did not survive correcting for multiple comparison (see Suppl.
Results).
Given the absence of a group mean difference on the HDRS-17,
but an overall strong and similar clinical response in both groups,
we tested whether unspecific effects reported for high-technology
augmentation therapy could be rejected. For example, an
improvement of 5.5 points on the HDRS-17 was reported for
sham whole-body hyperthermia (WBH) treatment [17]. Based on
the complete sample (N= 32) we carried out a one-sample two-
sided t-test against a test value of 6 found that our effect was
significantly larger than that expected placebo response (t 31=
2.385, p= 0.023, Cohen’s d= 0.422 [95% CI 0.057 to 0.780]).
Self-efficacy and clinical improvement
The exploratory robust regression analysis suggested that changes
in self-efficacy predicted residualized depression scores at the
primary endpoint (R2= 0.18, adjusted R2= 0.15, β=−0.187 ±
0.073, Fig. 2c), such that increase in self-efficacy was associated
with less depression severity (t30=−2.551, p= 0.016).
Region of interest analysis
Patients from both groups received neurofeedback training from
target ROIs of similar size (measured in number of mm3 voxels in
Talairach space; NFE= 2190 ± 293 vs NFS= 2913 ± 342, t158=
−1.606, p= 0.110). Patients upregulated the target ROIs during all
neurofeedback sessions (session 1: t31= 4.723; pFDR < 0.002,
session 2: t31= 2.772, pFDR= 0.011; session 4: t31= 3.726, pFDR=
0.002; session 5: t31= 3.809, pFDR= 0.002; Fig. 3), but not during
the transfer session (session 3: t31= 1.404; pFDR= 0.170). The
difference between the average upregulation across neurofeed-
back sessions and the transfer session was significant (t31= 2.397,
p= 0.023). There was no evidence for an effect of group (F1,30=
0.12, p= 0.73), session (F4,120= 1.965, p= 0.104), or group × time
interaction (F4,120= 0.160, p= 0.958). Further, an equivalence test
suggested that both groups activated ROIs to a similar extent
(t29.8= 1.702, p= 0.049, raw score lower limit 90% CI=−1.795
and upper limit 90% CI= 1.290).
Whole-brain analysis
Figure 4a shows the distribution of the main locus for target
region locations of the NFE and NFS groups (but see also Fig. S1
for more details). Patients in the NFE group were primarily trained
on anterior brain areas (e.g., insular and striatum), patients in the
NFS group mainly trained on the PPA. Figure 4b shows brain
regions involved in the neurofeedback training (contrast regulate
> rest). For the NFE group, limbic and subcortical regions (e.g., the
insula, caudate, and hippocampus) were activated while the
dorsolateral prefrontal cortex was deactivated (Fig. 4b; Table S3).
For the NFS group, mainly higher visual areas were activated
including the bilateral PPA as the main target region of this group
(Table S3). A direct group comparison (contrast NFE > NFS)
suggested that the NFS group showed more activation of the
PPA and frontal regions (Fig. 4c and Table S4).
DISCUSSION
We demonstrate feasibility and clinical efficacy of fMRI neurofeed-
back training in medicated patients with a longstanding history of
clinical depression. Neurofeedback training of emotional areas
was not superior to the control neurofeedback intervention.
Nonetheless, both intervention groups showed a clinically
significant improvement of the primary outcome measure with
over 40% reduction in the HDRS-17. The overall remission rate was
about 38%. Importantly, both measures were maintained, if not
slightly improved at follow-up (Fig. 2a, b). Further, both groups
improved to a similar extent on the secondary clinical outcome
measures of anxiety and depression and reported positive effects
on their quality of life. Taken together, this trial reproduced and
extended findings from a recent placebo-controlled fMRI-NF RCT
in unmedicated patients [8].
The whole-brain analysis of the NFE group showed activation of
the insula and the ventral striatum, indicating that patients
engaged in emotion self-regulation. This is encouraging because
striatal areas and the insula have been linked to positive
reappraisal of emotions [29]. Both emotion self-regulation and
reappraisal constitute important elements in psychotherapeutic
treatment for depression; however, they can be impaired in
depressed patients [30]. Our data suggest that fMRI-NF training
could indeed help patients in training this capacity. Of interest,
activated voxels in the NFS and NFE partly overlapped, mainly in
the anterior insula (Fig. 4b and Table S3). The (anterior) insula has
been implicated in various cognitive tasks that may explain this
Fig. 3 ROI analysis. Average t-value of target ROIs for each session. Pooled mean shown, as well as means for both groups with error bars
showing standard error of the mean (SEM). *p < 0.05 at FDR correction
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overlap, including its involvement in the integration of visual
information that is required for mental imagery of scenes [31], self-
regulation of affective as well as executive functions [32, 33], and
online monitoring of performance [34], a factor for which groups
were matched. Without more fine-grained fMRI measurements,
however, we cannot determine if the overlapping clusters
between groups reflect activation of the same neuronal popula-
tions. On a more general level, though, this overlap highlights the
difficulty of selecting strictly separated target networks for
different neurofeedback conditions.
A key question is why the active control neurofeedback group
(NFS) also showed a substantial clinical improvement. The
improvement of the NFS group may be explained by a similarly
rewarding experience and the type of mental imagery training
patients engaged in. Both groups upregulated target ROIs to a
similar extent, as shown by equivalence tests. Hence, also
participants in the NFS group experienced success of self-
regulation and they were positively reinforced for task success.
Generic psychological or physiological factors could thus be
important for any clinical efficacy of neurofeedback training in
depression. We have earlier suggested that self-regulation
experience during neurofeedback training may be associated
with an increase of self-efficacy and explain therapeutic effects of
fMRI-NF training in depression [7, 35]. This conjecture is supported
by an exploratory robust regression analysis between changes in
self-efficacy and residualized HDRS-17 scores (Fig. 2c). Self-efficacy
has been shown to mediate vulnerability to develop depressive
symptoms [36], as well as the effect of depression on developing
detrimental behavior including nicotine abuse [37]. The reported
changes in self-efficacy may thus yield secondary benefits
including less vulnerability to relapse and cognitive resources to
cope with challenges [27]. However, larger trials of longer duration
that include transfer task that engage similar processes are
needed to test whether self-efficacy may represent a psycholo-
gical mechanism underlying therapeutic effects of fMRI-NF
training [38]. We further note that the task of the NFS group—
imagining relaxing visual scenes—may also have had a ther-
apeutic effect. Relaxation therapies are used in clinical practice to
treat depression [39, 40]. Taken together, our active control group
likely received therapeutic self-regulation training and thus
showed substantial improvement. It is hence possible that our
control intervention was too conservative with respect to our aim
of showing superiority of targeting the affective brain.
Two (partly related) remaining questions are whether the
reported clinical findings are specific, and whether they are
comparable to effective active interventions or usual care. As the
current design did not include a sham-feedback or a care as usual
control group, we will argue based on epidemiological data that
the clinical effects reported here (1) exceed spontaneous
remission rates, (2) are comparable to clinical effects reported
for first line treatment as well as current best augmentation
treatment alternatives, and (3) exceed placebo effects reported for
sham-controlled high-technology therapies
First, the improvement of 40% on the HDRS-17 exceeds the
minimal clinically relevant improvement of about 27% [41] and
thus represents a substantial clinical effect. Findings also exceed
expected regression to the mean effects for chronically depressed
and partly treatment-resistant patients (the average duration of
Fig. 4 Whole-brain analysis. a Probability map (PM) of the localizer. b Activity of intervention groups, shown separately for NF-emotion and
NF-scene group. c Group contrast. Key areas are labeled with numbers: (1) Insular cortex/ ventrolateral prefrontal cortex, (2) parahippocampal
Place area (PPA), (3) supplementary motor area, (4) lingual gyrus, (5) premotor cortex, (6) superior parietal lobule, and (7) ventrolateral
prefrontal cortex. Statistical maps cluster-threshold corrected for multiple comparison (p < 0.001)
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illness was 19 years), for which epidemiological data only suggests
a rather sluggish improvement of 10–15% [42]. Further, given that
patients in our trial had received stable medication for at least
three months, the main response to pharmacological treatment
had likely already occurred before enrollment [43].
Second, the effects reported here across both groups for the
primary endpoint—about 8.3 points improvement and 37.5% [95%
CI 22.9 to 54.8] remission on the HDRS-17—are comparable to initial
responses found for first line pharmacological treatment (8 to 9
points improvement on the HDRS-17 and 36.8% remission) in
patients with comparable depression severity and chronicity [43, 44].
Indeed, the confidence interval around our remission rate excludes
the estimated remission rate (22%) for placebo groups in first level
pharmacotherapy treatment [45]. However, these comparisons seem
rather conservative given that patients received fMRI-NF as an
augmentation, or even as a second augmentation treatment (one
third of patients were already receiving combined pharmacological
treatment), because augmentation treatments usually yield gradually
less clinical improvement. Noteworthy, the presented clinical effects
are similar and partly larger than effects reported for other accepted
augmentation strategies: the “Sequenced Treatment Alternatives to
Relieve Depression” (STAR*D) trial reported on average 35%
remission for first augmentation, with about 36% for non-SSRIs
and 29.4% for behavioral therapy, and remission rates of only 20.5%
for secondary augmentation therapy [43].
Third, our clinical findings are also comparable to reported
effects of other high-tech interventions for depression. We note
that the size of non-specific treatment effects depends on
patients’ expectancies, beliefs, as well as the psychosocial context
[46], and non-specific treatment effects may thus be particularly
large for fMRI-NF. However, a recent sham-controlled RCT of fMRI-
NF of similar size in (unmedicated) depressed patients only found
a marginal improvement of 2 points (HDRS-21) and 6% remission
in a sham control group [8]. In contrast, their treatment group that
engaged in similar fMRI-NF training as our NFE group improved by
about 11.5 points and showed 32% remission. Likewise, our results
are comparable for treatment groups and outperform placebo
groups in other sham-controlled high-technology interventions
tested for depression: meta-analyses of transcranial magnetic
stimulation (TMS) trials suggest about 35% remission for
treatment groups, while sham TMS groups show only 5–10%
remission [47, 48]. Further, one whole-body hyperthermia (WBH)
trial reported an improvement of 8.3 points (HDRS-17) and a
remission rate of 40% remission for their treatment group, while
WBH sham only led to a placebo response of 5.5 points and 0%
remission [17]. Importantly, we could reject a large placebo
response of six points in an exploratory analysis, thereby showing
superiority of our clinical findings. Altogether, this survey of the
size of expected placebo responses suggests that the clinical
effects found in our trial exceed a mere regression to the mean or
placebo effect. Rather, our findings are comparable to treatment
effects reported for accepted augmentation therapies and other
high-technology therapies currently investigated in depression.
Another high-technology intervention tested in depression is
electroencephalography neurofeedback (EEG-NF). We have
reviewed the available literature earlier where we found that it
is limited to a small number of studies [35]. One randomized
single-blind EEG-NF trial observed improvements similar to those
as reported here (7.25 points improvement on the HDRS) after
5 weeks EEG-NF training [49], although we note that patients in
this trial were less severely depressed and partly already remitted
at baseline. An even larger improvement (from 21.38 to 6.23 on
the HDRS-17) was reported in a more recent 8-week open-label
(i.e., unblinded) study of EEG-NF [50]. However, both studies
lacked active self-regulation control groups and thus do not allow
estimating the expected placebo effect of EEG-NF in depression.
To test directly for a superiority of fMRI-NF over treatment-as-
usual and lower cost alternatives, future trials with larger sample
sizes could for instance pit neurofeedback against a non-MRI
based control intervention such as biofeedback, fMRI-informed
EEG-NF [51], or relaxation groups. Such a trial design would
address some of the non-specific effects that may play a role such
as exposure to technology, general self-regulation training,
enhancement of self-efficacy and reflection on bodily states.
However, it is important for us to consider the difference between
trying to identify the specific effects of fMRI-NF and trying to
ascertain if it is a treatment which is relatively more or less
effective than other active interventions or usual care. These will
naturally lead to different comparators in future studies [52].
In conclusion, we found no evidence for clinical superiority of
the self-regulation training of emotion areas over that of higher
visual areas. Both groups showed a clinical improvement that was
comparable to effects reported for treatment as usual and
exceeded expected regression to the mean and commonly
observed placebo effects. Hence, this trial demonstrated that if
moderately to severely depressed patients can upregulate a brain
area that is not immediately linked to affective processing (NFS
group), they can experience similar clinical benefits compared to
patients who completed emotion-focused neurofeedback training
(NFE group).We suggest that the experience of brain control and
the positive reinforcement of mental imagery may be necessary
components for therapeutic effects of neurofeedback and should
therefore be considered for future designs. Overall, neurofeedback
was well tolerated, but we would suggest that any clinical
neurofeedback protocols should be clinically supervised and entail
monitoring of mental strategies and psychological effects, so that
patients can discuss their individual experiences and protocols can
be adjusted if needed. We suggest that further exploration of the
clinical efficacy of real-time fMRI neurofeedback protocols and
neural as well as psychological mechanisms is needed.
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